Cerevel Therapeutics Holdings, Inc.
CERENASDAQHealthcare
$44.96
+$0.33(+0.74%)
Market Cap$8.2B
P/E Ratio—
52W High$44.99
52W Low$19.59
Cerevel Therapeutics Holdings, Inc. (CERE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CERE · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2024Report Date: Aug 7, 2024EPS Actual
-$0.63
Est. -$0.61 · -3.3%
Revenue
—
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Aug 7, 2024
After Market Close
▼ Miss EPS
CERE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.20
Rev. $3.00B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.20
Rev. Est.$3.00B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q3 FY2024 | Aug 7, 2024 | -$0.61 | -$0.63 | -3.3% | — | — | — |
| ▼ Q2 FY2024 | May 8, 2024 | -$0.66 | -$0.73 | -10.9% | — | — | — |
| ▼ Q2 FY2024 | May 1, 2024 | -$0.61 | -$0.73 | -19.7% | $0.01B | — | — |
| ▲ Q4 FY2023 | Nov 1, 2023 | -$0.63 | -$0.61 | +3.2% | — | — | — |
| ▲ Q3 FY2023 | Aug 2, 2023 | -$0.65 | -$0.63 | +3.1% | — | — | — |
| — Q2 FY2023 | May 3, 2023 | -$0.67 | -$0.67 | +0.0% | — | — | — |
| ▲ Q1 FY2023 | Feb 22, 2023 | -$0.64 | -$0.59 | +7.8% | — | — | — |
| ▼ Q4 FY2022 | Nov 8, 2022 | -$0.62 | -$0.66 | -6.5% | — | — | — |
Q3 FY2024
Aug 7, 2024Miss
EPS Actual
-$0.63
EPS Est.
-$0.61
EPS Surpr.
-3.3%
Revenue
—
Q2 FY2024
May 8, 2024Miss
EPS Actual
-$0.73
EPS Est.
-$0.66
EPS Surpr.
-10.9%
Revenue
—
Q2 FY2024
May 1, 2024Miss
EPS Actual
-$0.73
EPS Est.
-$0.61
EPS Surpr.
-19.7%
Revenue
$0.01B
Q4 FY2023
Nov 1, 2023Beat
EPS Actual
-$0.61
EPS Est.
-$0.63
EPS Surpr.
+3.2%
Revenue
—
Q3 FY2023
Aug 2, 2023Beat
EPS Actual
-$0.63
EPS Est.
-$0.65
EPS Surpr.
+3.1%
Revenue
—
Q2 FY2023
May 3, 2023
EPS Actual
-$0.67
EPS Est.
-$0.67
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2023
Feb 22, 2023Beat
EPS Actual
-$0.59
EPS Est.
-$0.64
EPS Surpr.
+7.8%
Revenue
—
Q4 FY2022
Nov 8, 2022Miss
EPS Actual
-$0.66
EPS Est.
-$0.62
EPS Surpr.
-6.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2025 | $-0.76 | $-0.76 | $-0.76 | 1 |
| Q2 FY2025 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Q1 FY2025 | $-0.72 | $-0.72 | $-0.72 | 1 |
| Q4 FY2024 | $-0.85 | $-0.85 | $-0.85 | 1 |
| Q3 FY2024 | $-0.86 | $-0.72 | $-0.50 | 3 |
| Q2 FY2024 | $-0.76 | $-0.76 | $-0.76 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2024 | Aug 7, 2024 | -3.3% | $44.96 | — | — |
| ▼ Q2 FY2024 | May 8, 2024 | -10.9% | $42.26 | $42.06 | -0.47% |
| ▼ Q2 FY2024 | May 1, 2024 | -19.7% | $42.71 | $42.63 | -0.19% |
| ▲ Q4 FY2023 | Nov 1, 2023 | +3.2% | $23.65 | $25.35 | +7.19% |
| ▲ Q3 FY2023 | Aug 2, 2023 | +3.1% | $30.65 | $26.33 | -14.09% |
| ▲ Q2 FY2023 | May 3, 2023 | +0.0% | $30.90 | $31.92 | +3.30% |
| ▲ Q1 FY2023 | Feb 22, 2023 | +7.8% | $31.00 | $26.73 | -13.77% |
| ▼ Q4 FY2022 | Nov 8, 2022 | -6.5% | $27.11 | $25.70 | -5.20% |
Q3 FY2024—
Report Date
Aug 7, 2024
EPS Beat/Miss
-3.3%
Price Before
$44.96
Price After
—
Q2 FY2024-0.47%
Report Date
May 8, 2024
EPS Beat/Miss
-10.9%
Price Before
$42.26
Price After
$42.06
Q2 FY2024-0.19%
Report Date
May 1, 2024
EPS Beat/Miss
-19.7%
Price Before
$42.71
Price After
$42.63
Q4 FY2023+7.19%
Report Date
Nov 1, 2023
EPS Beat/Miss
+3.2%
Price Before
$23.65
Price After
$25.35
Q3 FY2023-14.09%
Report Date
Aug 2, 2023
EPS Beat/Miss
+3.1%
Price Before
$30.65
Price After
$26.33
Q2 FY2023+3.30%
Report Date
May 3, 2023
EPS Beat/Miss
+0.0%
Price Before
$30.90
Price After
$31.92
Q1 FY2023-13.77%
Report Date
Feb 22, 2023
EPS Beat/Miss
+7.8%
Price Before
$31.00
Price After
$26.73
Q4 FY2022-5.20%
Report Date
Nov 8, 2022
EPS Beat/Miss
-6.5%
Price Before
$27.11
Price After
$25.70
Avg Beat Reaction-4.34%
Avg Miss Reaction-1.95%
Beat Rate4 / 8 quarters
Largest Move-14.09% (Q3 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CERE ends December
Cerevel Therapeutics Holdings, Inc. (CERE) most recently reported earnings on August 7, 2024 for Q3 FY2024, posting EPS of $-0.63 — missing the analyst consensus of $-0.61 by -3.3%. The next CERE earnings date is expected around September 1, 2026.
Each quarter, investors track CERE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CERE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CERE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CERE earnings · 5 questionsCerevel Therapeutics Holdings, Inc.'s next earnings report is expected around September 1, 2026. CERE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CERE historically reports after market close (AMC).
CERE earnings datewhen is CERE earningsCERE next earnings datewhen does CERE report earningsCERE earnings calendar
▸ Source: FMP · Cerevel Therapeutics Holdings, Inc. SEC filings · US GAAP · Cerevel Therapeutics Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026